Does methotrexate increase the risk of infection or malignancy? (Q38555334)

4 September 2017

1 reference

title

Does methotrexate increase the risk of infection or malignancy? (English)

1 reference

4 September 2017

1 reference

Kanik KS

1 reference

4 September 2017

Cash JM

series ordinal

1 reference

4 September 2017

publication date

1 November 1997

1 reference

Rheumatic Diseases Clinics of North America

4 September 2017

published in

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

955-967

1 reference

Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Cryptococcosis associated with low-dose methotrexate for arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Primitive neuroectodermal tumor presenting as a delayed sequela to cranial irradiation and intrathecal methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate-Induced Carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Molecular therapeutics. Methotrexate and its mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Toxicity of immunosuppressive drugs in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Cutaneous cryptococcosis in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Incidence of Cancer Among Patients With Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate: Assessment of In Vivo Clastogenicity and Carcinogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Malignancy During Methotrexate and Steroid Therapy for Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate therapy in rheumatoid arthritis patients diminishes lectin-induced mononuclear cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Cytogenetic effects of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Increased Risk of Lymphoma in Sicca Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Paraproteins in rheumatoid arthritis and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Rheumatoid arthritis, methotrexate therapy, and Pneumocystis pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Sister chromatid exchange in patients treated with methotrexate for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Induction of malignant transformation and mutagenesis in cell cultures by cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

[Fatal infectious complications in 2 patients with adult onset Still disease]

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

PNEUMOCYSTIS CARINII INFECTION COMPLICATING CYTOTOXIC THERAPY IN TWO PATIENTS WITH LYMPHOPENIA, BUT A NORMAL TOTAL WHITE CELL COUNT

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Progressive pulmonary infiltrates in a patient with polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Life-span carcinogenicity tests with 4-amino-N10-methylpteroylglutamic acid (methotrexate) in Swiss mice and Syrian golden hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

No Increase in Second Tumors after Cytotoxic Chemotherapy for Gestational Trophoblastic Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Chromosomal abnormalities produced by folic acid antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Low-dose methotrexate and cholangiocarcinoma of the common hepatic duct

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate: mechanism of action in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate, pneumonitis, and infection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Long-term experience with low dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Three cases of malignant neoplasm, pneumonitis, and pancytopenia during treatment with low-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Fatal pneumocystis pneumonia in asthmatic patient treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Frequency of infections among rheumatoid arthritis patients, before and after disease onset

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Fatal Cytomegalovirus pneumonia in a patient receiving corticosteroids and methotrexate for mixed connective tissue disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

Constitutive fragile sites and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970368-9

7 January 2021

10.1016/S0889-857X(05)70368-9

Identifiers

DOI

1 reference

4 September 2017

1 reference